The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes with Radium-223 therapy in clinical practice of metastatic castration resistant prostate cancer (mCRPC).
 
Ajjai Shivaram Alva
Honoraria - Eisai
Consulting or Advisory Role - Eisai
Research Funding - BIND Biosciences; Bristol-Myers Squibb; Genentech; Novartis; Oncogenex
 
Luke T. Nordquist
No Relationships to Disclose
 
Stephanie Daignault
No Relationships to Disclose
 
Saby George
Employment - Amgen (I)
Consulting or Advisory Role - Astellas Pharma; Bayer; Novartis; Sanofi
Research Funding - Exelixis; GlaxoSmithKline
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Sanofi
 
Jorge Ramos
No Relationships to Disclose
 
Sudhir Isharwal
No Relationships to Disclose
 
Matthew McDonald
Consulting or Advisory Role - Bayer
 
Gregory Campbell
Travel, Accommodations, Expenses - Roche/Genentech
 
Pongwut Danchaivijitr
No Relationships to Disclose
 
Costantine Albany
No Relationships to Disclose
 
Evan Y. Yu
Honoraria - Amgen; Bayer; Dendreon; Janssen; Medivation; Sanofi
Consulting or Advisory Role - Amgen; Dendreon; Janssen; Medivation; Sanofi
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); GTx (Inst); ImClone Systems (Inst); Janssen (Inst); Oncogenex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dendreon; Janssen; Medivation